06:05 AM EDT, 06/05/2026 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday in a Form 8-K filing with the US Securities and Exchange Commission that Nicholas Maestas has resigned from his position as chief financial officer, effective Friday.

The company did not name a direct successor, though it appointed corporate controller Justin Trojanowski to the additional role of principal financial officer.